High court rejects case on Lipitor's patent term

April 03, 2007|By Bloomberg News

WASHINGTON -- Pfizer Inc. fought off a U.S. Supreme Court appeal that aimed to open the company's Lipitor cholesterol pill, the most widely prescribed drug in the world, to generic competition.

The high court, without comment, turned away yesterday arguments from Indian drugmaker Ranbaxy Laboratories Ltd., which sought to block a patent extension that protects Lipitor in the United States through March 2010. A federal appeals court upheld the extension in August.

Lipitor had sales of $12.9 billion last year and accounts for as much as 40 percent of Pfizer's profit. Separately, the company is asking federal patent examiners to reissue a second patent that would prevent generic competition until June 2011.

Ranbaxy argued that Pfizer forfeited its right to an extension by failing to disclose important information to the U.S. Patent and Trademark Office. Pfizer urged the Supreme Court not to hear the appeal.

"The Supreme Court has declined to intervene in the appeals court's ruling in favor of our very strong basic patent and that, of course, is a very good thing for Pfizer," Pfizer spokesman Bryant Haskins said. A Ranbaxy spokesman declined to comment.

Pfizer has lost patent protection on a succession of products including the epilepsy drug Neurontin, the antibiotic Zithromax and the antidepressant Zoloft. On March 22, a federal appeals court invalidated the drugmaker's patent on Norvasc, a hypertension drug.

Lipitor faces competition from cheaper generic copies of Merck & Co.'s Zocor cholesterol-reducer, which lost patent protection in June. Pfizer is also trying to protect its Lipitor sales against newer, more potent cholesterol pills that are gaining market share, such as Merck and Schering-Plough Corp.'s Vytorin.

The patent at issue in the Supreme Court case originally was set to expire in May 2006. U.S. government agencies extended the term to 2009 to compensate Pfizer for the time it spent to get Food and Drug Administration approval for Lipitor. Pfizer got an additional extension of six months, to March 2010, because it planned to test the drug's effects on children.

Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.